1Hu RH, Lee PH, Yu SC, et al. Surgical resection for recurrent hepatoeellular carcinoma: Prognosis and analysis of risk factors[J]. Surgery, 1996, 120(1) :23-29.
2Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma [ J ]. Ann Surg, 2003,238 (5) : 703 - 710.
3Chen HY, Juan CC, Ker CG. Laparoscopic liver surgery for patients with hepatocellular carcinoma [J]. Ann Surg Oncol, 2008,15(3) : 800-806.
4Belli G, Fantini C, D'Agostino A, et al. Laparoscopic versus open liver resection for hepatocellular carcinoma in patients with histologically proven cirrhosis: Short- and middle-term results [ J ]. Surg Endose, 2007,21 ( 11 ) : 2004-2011.
5Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival [J]. Hepatology, 2001,33 (6) : 1394-1403.
6Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: A 22-year experience with 467 patients at UCLA [Jl. Ann Surg, 2007,246(3):502-509; discussion 509-511.
7Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatoeellular carcinoma[J]. Ann Surg, 2006,243 ( 3 ) : 321-328.
8Curley SA, Izzo F, Ellis LM, et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis[J]. Ann Surg, 2000,232(3) :381-391.
9Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8 510 patients [J]. Gastroenterology, 2006, 131 (2) : 461-469.
10Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma [ J ]. Hepatology, 2002,35 ( 5 ) : 1164- 1171.
3Burnet FM. Immunological Surveillance in Neoplasia[-J]. Trans plant. Rev,1971,7 (1) :3-25.
4Wieder T,Braumtiller HBrenner E, et al. Changing T-cell enig ma: Cancer killing or cancer control[J]. Cell Cycle, 2013,12(19) 3146-3153.
5Sakaguchi S,Sakaguchi N, Asano M, et al. Immunologic self-toler ance maintained by activated T cells expressing IL-2 receptor al pha-chains (CD25). Breakdown of a single mechanism of self-tol erance causes various autoimmune diseases[J]. J Immunol, 1995, 155(3) :1151-1164.
6Sakaguchi S. Naturally arising CD4+ regulatory T cells for immu- nologic self-tolerance and negative control of immune responses [J]. Annu Rev Immunol,2004,2:531-562.
7Trzonkowski P,Szmit E,Mysliwska J et al. CD4+ CD25+ T regu- latory cells inhibit cytotoxic activity of CTL and NK cells in hu mans impact of immuno senescence[J]. Clin Immunol, 2006,119: 307-316.
8Degl'Innocenti E, Grioni M, Capuano G, et al. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+ CD25+ regulatory T cells [J]. Cancer Res, 2008, 68 ( 1 ) : 292-300.
9Curiel TJ,Coukos G, Zou L, et al. Specific recruitment of regula- tory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[J. Nat Med, 2004,10(9) : 942-949.
10Sasada T, Kimura M, Yoshida Y, et al. CD4 + CD25 + regulatory T cells in patients with gastrointestinal malignancies., possible in- volvement of regulatory T cells in disease progression[J]. Cancer, 2003,98(5) : 1089-1099.
